MedTrace Logo

Azilect + Antidepressant Chart Review

NCT00955604 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1500

Last updated 2017-02-06

No results posted yet for this study

Summary

To identify the occurrence of serotonin toxicity in Parkinson's Disease (PD) patients receiving antidepressant therapy and rasagiline, compared to those receiving rasagiline without antidepressant medications and compared to PD patients receiving antidepressants, but not rasagiline.

Conditions

  • Serotonin Syndrome

Interventions

DRUG

Group R+AD Rasagiline + Antidepressant

Rasagiline and an antidepressant (SRIs, SNRIs, St. John's wort and/or TCAs) at least 14 days

DRUG

Group R Rasagiline

At least 2 months of rasagiline

DRUG

Group AD Anti-PD + Antidepressant

An approved dopaminergic medication for PD. (2 months of treatment with an antidepressant medication.

Sponsors & Collaborators

  • Teva Branded Pharmaceutical Products R&D, Inc.

    lead INDUSTRY

Principal Investigators

  • Tom Smith, MD · Teva Neuroscience, Inc.

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2010-03-31
Completion
2010-06-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00955604 on ClinicalTrials.gov